Select a medication above to begin.
Zoryve
roflumilast topical
Adult Dosing .
Dosage forms: CRM: 0.15%, 0.3%; FOAM: 0.3%
psoriasis, plaque
- [apply 0.3% cream or foam qd]
psoriasis, scalp
- [apply 0.3% foam qd]
atopic dermatitis, mild-moderate
- [apply 0.15% cream qd]
seborrheic dermatitis
- [apply 0.3% foam qd]
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class B or C: contraindicated
Peds Dosing .
- Dosage forms: CRM: 0.15%, 0.3%; FOAM: 0.3%
psoriasis, plaque
- [0.3% cream form, 6 yo and older]
- Dose: apply qd
- [0.3% foam form, 12 yo and older]
- Dose: apply qd
psoriasis, scalp
- [12 yo and older]
- Dose: apply 0.3% foam qd
atopic dermatitis, mild-moderate
- [6 yo and older]
- Dose: apply 0.15% cream qd
seborrheic dermatitis
- [9 yo and older]
- Dose: apply 0.3% foam qd
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class B or C: contraindicated
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hepatic impairment, Child-Pugh Class B-C
- labor and delivery
- breast admin. (breastfeeding pts)
Drug Interactions .
Overview
roflumilast topical
PDE4 inhibitor topical
- CYP1A2 substrate
- CYP3A4 substrate
Caution Advised
- acyclovir
- adagrasib
- allopurinol
- alprazolam
- amiodarone
- amlodipine
- aprepitant
- asciminib
- atazanavir
- atorvastatin
- avacopan
- belumosudil
- berberine
- berotralstat
- bicalutamide
- caffeine
- caffeine citrate
- cannabidiol
- cannabis
- capivasertib
- capmatinib
- ceritinib
- chloramphenicol
- chlorzoxazone
- cilostazol
- cimetidine
- ciprofloxacin
- clarithromycin
- clofazimine
- cobicistat
- conivaptan
- cranberry
- crizotinib
- cyclosporine
- danazol
- danshen
- daridorexant
- darunavir
- deferasirox
- diazoxide
- diltiazem
- diosmin
- disulfiram
- dronedarone
- duvelisib
- echinacea
- efavirenz
- enasidenib
- entrectinib
- erythromycin
- estradiol (contraceptive)
- estradiol (hormone replacement)
- estrogens, conjugated (hormone replacement)
- estrogens, esterified (hormone replacement)
- ethinyl estradiol (contraceptive)
- ethinyl estradiol (hormone replacement)
- everolimus
- famotidine
- fedratinib
- fexinidazole
- flibanserin
- fluconazole
- fluvoxamine
- fosamprenavir
- fosaprepitant
- fostamatinib
- gepotidacin
- ginkgo
- ginseng, Asian
- givosiran
- glecaprevir
- goldenseal
- grazoprevir
- idelalisib
- imatinib
- interferon beta 1a
- interferon beta 1b
- isavuconazonium
- isoniazid
- istradefylline
- itraconazole
- ivacaftor
- ketoconazole
- kratom
- lapatinib
- larotrectinib
- lazertinib
- lefamulin
- lenacapavir
- leniolisib
- letermovir
- levoketoconazole
- lomitapide
- lonafarnib
- lopinavir/ritonavir
- lovastatin
- lurasidone
- maribavir
- mavorixafor
- methoxsalen
- mexiletine
- mifepristone
- nefazodone
- nelfinavir
- netupitant
- nicardipine
- nilotinib
- nirogacestat
- obeticholic acid
- osilodrostat
- pacritinib
- palbociclib
- pazopanib
- peginterferon alfa 2a
- pentoxifylline
- peppermint
- pibrentasvir
- pirtobrutinib
- posaconazole
- propafenone
- propranolol
- quercetin
- ranolazine
- remdesivir
- resveratrol
- ribociclib
- ritlecitinib
- ritonavir
- rucaparib
- safinamide
- selpercatinib
- spironolactone
- stiripentol
- ticagrelor
- tipranavir
- tolvaptan
- treosulfan
- trofinetide
- tucatinib
- valacyclovir
- vemurafenib
- verapamil
- viloxazine
- vonoprazan
- voriconazole
- voxelotor
- zileuton
Adverse Reactions .
Serious Reactions
may occur but none reported
Common Reactions
- diarrhea
- headache
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy, avoid use during labor and delivery; no human data available; risk of embryo-fetal toxicity, incl. stillbirth, and delivery retardation based on animal data w/ PO form
Lactation
Clinical Summary
avoid use on breast while breastfeeding, otherwise weigh risk/benefit on other areas; no human data available to assess risk of infant harm, though possible drug excretion into milk based on drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: liver extensively; CYP450: 1A2, 3A4 substrate; Info: active metabolite; some systemic absorption
Excretion: urine 70%; Half-life: 3.6-5 days
Subclass: Atopic Dermatitis, Topical Nonsteroidal Agents ; Phosphodiesterase 4 (PDE4) Inhibitors, Dermatologic ; Psoriasis, Topical Nonsteroidal Agents ; Seborrheic Dermatitis/Dandruff
Mechanism of Action
exact mechanism of action unknown; inhibits phosphodiesterase type 4 (PDE4), leading to increased intracellular cAMP levels
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.